To a large extent, the specificity of cancer immunotherapy is dependent on the recognition of specific tumor antigens, especially neoantigens. Neoantigens are a kind of tumor antigen derived from tumor-specific somatic mutations. They are highly restricted to tumor cells, with minimally established immune tolerance. Neoantigen-based cancer vaccines have shown promising therapeutic effects in clinical settings. Furthermore, a growing body of evidence indicates that neoantigen-specific T cells underlie the success of the recent surge in immune checkpoint inhibitor therapy. Although the origin of neoantigens has been discussed extensively in the literature, the identification of neoantigens, their significance, and their influence in clinical practice are largely ignored.
The application of neoantigens is rapidly becoming more widespread in clinical settings; not only just related to the development of tumor vaccine or adoptive cell therapy but also in the monitoring of therapy response in immune checkpoint blockade and other therapies as well. This Research Topic focuses on the clinical application of neoantigens and how we can use them to guide our daily practice, modify canonical therapies, and develop novel strategies for cancer therapy. We will also discuss the challenges in the clinical application of neoantigens.
This Research Topic welcomes the submission of Original Research, Reviews and Methods, on themes including, but not limited to:
? Methods to detect and monitor the dynamic changes of neoantigens in a clinical setting.
? Neoantigens as a tool to guide clinical decisions on tumor treatment.
? Methods for the development of neoantigen-specific therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
To a large extent, the specificity of cancer immunotherapy is dependent on the recognition of specific tumor antigens, especially neoantigens. Neoantigens are a kind of tumor antigen derived from tumor-specific somatic mutations. They are highly restricted to tumor cells, with minimally established immune tolerance. Neoantigen-based cancer vaccines have shown promising therapeutic effects in clinical settings. Furthermore, a growing body of evidence indicates that neoantigen-specific T cells underlie the success of the recent surge in immune checkpoint inhibitor therapy. Although the origin of neoantigens has been discussed extensively in the literature, the identification of neoantigens, their significance, and their influence in clinical practice are largely ignored.
The application of neoantigens is rapidly becoming more widespread in clinical settings; not only just related to the development of tumor vaccine or adoptive cell therapy but also in the monitoring of therapy response in immune checkpoint blockade and other therapies as well. This Research Topic focuses on the clinical application of neoantigens and how we can use them to guide our daily practice, modify canonical therapies, and develop novel strategies for cancer therapy. We will also discuss the challenges in the clinical application of neoantigens.
This Research Topic welcomes the submission of Original Research, Reviews and Methods, on themes including, but not limited to:
? Methods to detect and monitor the dynamic changes of neoantigens in a clinical setting.
? Neoantigens as a tool to guide clinical decisions on tumor treatment.
? Methods for the development of neoantigen-specific therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
